Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model

Table 2 Mean cost for cardiovascular procedures and hospitalizations during the period from 2013 to 2019 in Brazilian SUS

	Brazilian SUS (mean cost in Int$)
Outpatient care (annual cost)
Diabetes with no complications (Stage A)	2,018.00
Diabetes with heart failure (Stage B)	7,458.00
Diabetes with ACS or stroke (Stage C)	5,536.00
Haemodialysis (annual cost)	9,113.00
Procedures typically performed (per 1 procedure)
PCI	6,328.00
CABG	12,655.00
Intensive care unit (ICU) hospitalization (per day)^a	555.00
In-patient care by condition treated (per 1 hospitalization)
Heart failure^a	1,252.00
Diabetes^a	497.00
Cardiac arrest^a	2,000.00
Unstable angina^a	1,112.00
Myocardial infarction^a	1,778.00
Ischemic stroke^a	3,321.00
Haemorrhagic stroke^b	7,043.00

We used the reimbursement costs for procedures, ICU hospitalizations and in-patient care to estimate mean annual cost related to relevant clinical events (RECE) including hemodialysis and their relative incidences in patients-years observed in B-CaRe:QCO and BDS cohorts. RECE-related mean annual costs were as follows: Stage A (asymptomatic) = Int$ 1,083.00; Stage B (heart failure) = Int$ 1,278.00; Stage C (coronary artery disease or stroke) = Int$ 2,059.00; Stage D (dead) = Int$ 0.00
^aCost of hospitalization (includes lab and imaging exams and the cost for beds during average length of hospital stay), not including the costs for procedures
^bIncludes the costs for procedures and hospitalizations. Data for Brazil obtained from DATASUS (SIH/SUS and SIGTAP), the data processing system of the Brazilian Health Ministry

ISSN: 2191-1991